NCT00160238View on ClinicalTrials.gov

Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2003

Conditions
Meniere's Disease
Interventions
DRUG

Betahistine 24 mg bid (Betaserc)

Trial Locations (1)

Unknown

Site 1, Marseille

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00160238 - Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy | Biotech Hunter | Biotech Hunter